Sichuan Biokin PharmaceuticalLtd Full Year 2024 Earnings: Revenues Disappoint

Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥5.82b (up by CN¥5.26b from FY 2023).
• Net income: CN¥3.71b (up from CN¥780.5m loss in FY 2023).
• Profit margin: 64% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
• EPS: CN¥9.25 (up from CN¥1.95 loss in FY 2023).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sichuan Biokin PharmaceuticalLtd Revenues Disappoint

Revenue missed analyst estimates by 3.8%. Earnings per share (EPS) was mostly in line with analyst estimates.

Looking ahead, revenue is expected to decline by 43% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in China are expected to grow by 11%.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 10% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Sichuan Biokin PharmaceuticalLtd that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.